Wedoany.com Report on Feb 3rd, Finnish Prime Minister Petteri Orpo hosted a reception at the Finnish Ambassador's residence in China. Dr. Sun Xiulian, Chairman and CTO of Biogenesys Co., Ltd. and a representative from China's biopharmaceutical sector, was invited to attend. The event brought together senior Finnish government officials and corporate delegates to discuss the future of Advanced Therapy Medicinal Products (ATMP) collaboration. The following day, the Sixth Meeting of the China-Finland Innovation Enterprise Cooperation Committee was held at the Ministry of Commerce. Dr. Sun Xiulian, alongside representatives such as Juha Yrjänheikki, CEO of Finnish company AUREALIS THERAPEUTICS, signed agreements to initiate multilateral cooperation on Cell and Gene Therapy (CGT) drug projects, encompassing aspects like Phase III clinical trials and process validation stage manufacturing.
As China's pharmaceutical capabilities gain international recognition, Chinese biopharmaceutical companies are accelerating their global expansion. The export structure is upgrading towards high-value-added areas such as innovative drugs and advanced formulations. Against this backdrop, Biogenesys Co., Ltd., with its profound technological expertise, global production capacity layout, and extensive regulatory submission experience, occupies a significant position in the global CGT industry chain. It serves as a crucial bridge connecting Chinese innovation with the global market.
Biogenesys Co., Ltd. has established four core technology platforms: plasmid, viral vector, cell therapy, and RNA products. It boasts a comprehensive global production service network and a complete FDA Drug Master File (DMF) library, building an efficient and reliable international "fast track" for ATMP companies both in China and abroad. This collaboration will leverage Biogenesys Co., Ltd.' commercial-scale Beijing facility to carry out production tasks. This facility features manufacturing spaces compliant with regulatory requirements in China, the EU, and the US, providing internationally standardized production capacity assurance for the project.
Biogenesys Co., Ltd. will continue to deepen global cooperation, leveraging its end-to-end technology and global footprint to propel more ATMP innovative therapies towards clinical application, ultimately benefiting patients worldwide.
